Katarzyna Bliźniewska-Kowalska1, Bernadeta Szewczyk2, Małgorzata Gałecka3, Kuan-Pin Su4, Michael Maes5, Janusz Szemraj6, Piotr Gałecki1. 1. Department of Adult Psychiatry, Medical University of Lodz, 91-229 Lodz, Poland. 2. Department of Neurobiology, Maj Institute of Pharmacology Polish Academy of Sciences, 31-343 Cracow, Poland. 3. Department of Psychotherapy, Medical University of Lodz, 91-229 Lodz, Poland. 4. An-Nan Hospital, China Medical University, Tainan 709, Taiwan. 5. Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 6. Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
Abstract
(1) Background: Activated immune-inflammatory pathways play an important role in the pathogenesis of depression and pathological obesity. Obesity might promote production of cytokine interleukin 17, which plays a significant role in neuro-immune reactions. The study aimed at assessing the relationship between Body Mass Index (BMI) and IL-17 expression, taking into account the clinical psychiatric variables in patients with depression. (2) Methods: A total of 125 participants took part in the study (95 depressed patients, 30 healthy controls). Data concerning the course of depressive disorders and BMI were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Reverse transcription polymerase chain reaction (RT-PCR) was used to assess IL-17 gene expression at the mRNA levels, while enzyme-linked immunosorbent assay (ELISA) was used to assess IL-17 expression at the protein level. (3) Results: Patients with more hospitalizations showed significantly higher IL-17 mRNA expression levels and higher BMI. However, no correlation between BMI and IL-17 expression was found in depressed patients. (4) Conclusions: Our study revealed that BMI does not affect IL-17 expression in patients with depression. However, further studies should be conducted to evaluate the effects of IL-17 inhibition on adipose tissue and vice versa.
(1) Background: Activated immune-inflammatory pathways play an important role in the pathogenesis of depression and pathological obesity. Obesity might promote production of cytokine interleukin 17, which plays a significant role in neuro-immune reactions. The study aimed at assessing the relationship between Body Mass Index (BMI) and IL-17 expression, taking into account the clinical psychiatric variables in patients with depression. (2) Methods: A total of 125 participants took part in the study (95 depressedpatients, 30 healthy controls). Data concerning the course of depressive disorders and BMI were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Reverse transcription polymerase chain reaction (RT-PCR) was used to assess IL-17 gene expression at the mRNA levels, while enzyme-linked immunosorbent assay (ELISA) was used to assess IL-17 expression at the protein level. (3) Results:Patients with more hospitalizations showed significantly higher IL-17 mRNA expression levels and higher BMI. However, no correlation between BMI and IL-17 expression was found in depressedpatients. (4) Conclusions: Our study revealed that BMI does not affect IL-17 expression in patients with depression. However, further studies should be conducted to evaluate the effects of IL-17 inhibition on adipose tissue and vice versa.
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: Mohammad Hasan Davami; Rasoul Baharlou; Abbas Ahmadi Vasmehjani; Ahmad Ghanizadeh; Mitra Keshtkar; Iman Dezhkam; Mohammad Reza Atashzar Journal: Basic Clin Neurosci Date: 2016-04
Authors: A Deodhar; P J Mease; I B McInnes; X Baraliakos; K Reich; A Blauvelt; C Leonardi; B Porter; A Das Gupta; A Widmer; L Pricop; T Fox Journal: Arthritis Res Ther Date: 2019-05-02 Impact factor: 5.156